(CercleFinance.com) – Deinove publishes a net result of -7.0 million euros for the past year, against -7.3 million in 2020, mainly thanks to the 12% reduction in operating expenses to 7 .9 million (still 83% devoted to R&D).
The biotechnology company recorded 594,000 euros in operating income over the financial year (compared to 836,000 euros in 2020), including 174,000 euros in subsidies paid and 367,000 euros in turnover within the framework of collaborative research agreements.
Deinove claims a cash balance of +3.8 million euros at the end of 2021, against +2.9 million a year earlier. In January, a third tranche of convertible bonds was subscribed by ESGO Fund, under the contract put in place last November.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
